Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm neoadjuvant pyrotinib plus chemotherapy in HR-positive, HER2-low breast cancer
ChiCTR2100047233Phase 2Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Residual cancer burden 0/I rate. Started Jun 2021; status: completed.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100047233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047233.